48 results about "Protein kinase A" patented technology

The invention discloses a process for preparing human serum albumin. According to the process, a low-temperature ethanol separation method is adopted, and the human serum albumin is prepared from human plasma. The process comprises the steps of dissolving plasma; preparing an ingredient I; preparing an ingredient II and an ingredient III; preparing an ingredient IV; preparing an ingredient V; refining the ingredient V; carrying out ultrafiltration; diluting; carrying out pasteurization; sterilizing and packaging albumen; incubating products; and packaging finished products. The process has the advantages that solid-liquid separation is carried out by adopting a pressure filtration technology, so that the albumin yield which is higher than 29 g / L plasma is increased remarkably, the purity is higher than 98%, and the stability of the products is improved remarkably; Zetaplus deep filter-core filtration is combined with the prolongation of pasteurization time, so that the PKA (Protein Kinase A) level of the products is effectively controlled to be lower than 20IU / ml, and the risks of excessive heat source and virus infection in the products are reduced; and during the process, sodium chloride solutions of two gradient concentrations are used for carrying out ultrafiltration, so that not only can the ethanol residual quantity of the products be controlled to be lower than 0.025%, but also the aluminum residual quantity can be effectively minimized to be lower than 50 micrograms / L.

A method for measuring protein kinase activity comprising:(a) providing a first solution comprising ATP and a protein kinase to be tested, and a second solution comprising ATP in the absence of said kinase to be tested;(b) adding a substrate capable of being phosphorylated by the protein kinase to be tested to the first and second solutions of step (a);(c) measuring the concentration of ATP and / or ADP, or the rate of change thereof with respect to time, in each of the reaction mixtures formed in step (b) using a bioluminescence reaction; and(d) using the information about the concentration of ATP and / or ADP to determine the activity of the protein kinase to be tested.

Provided herein are methods and compositions for limiting development of and / or treating diabetes, involving compounds of formula A-B, wherein A is a pancreatic β cell targeting moiety, and B is an inhibitor of expression and / or activity of Apolipoprotein CIII (apoCIII), protein kinase A (PKA), Src kinase, and / or β1 integrin.

The insecticides of the invention target the downstream portions of the signaling sequence of B. thuringiensis toxin, specifically protein kinase A (PKA) or adenylate cyclase (AC).

Pharmaceutical compositions useful for treating immunosuppressive disease and containing compounds capable of inhibiting cAMP-dependent protein kinase A (PKA) as well as use of the same, are described.

The invention discloses a method for improving the dyeing performance of a wool fiber product through enzymatic modification, and belongs to the technical field of textile biology. Wool pretreatment is performed through hydrogen peroxide; protein kinase A is combined for catalyzing serine and threonine residues phosphorylation in the wool, so that more electronegative groups are generated on the fiber surface; the dyeing of cationic dye on the wool fiber is realized; the dyeing performance of the wool fiber product is improved. The method comprises the following concrete steps of (1) wool hydrogen peroxide pretreatment; (2) wool phosphorylation catalyzed by protein kinase A; (3) cationic dye dyeing; (4) water washing and drying aftertreatment. Compared with a method that the electronegative groups are introduced onto the wool through a chemical method, and realizing the cationic dye wool dyeing, the method disclosed by the invention has the advantages that the enzymic catalytic reaction efficiency is high; the wool phosphorylation reaction conditions are mild; the dyeing performance of the wool fiber product is obviously improved.

Provided is a yeast strain capable of excessively synthesizing cAMP and its construction method and fermentation technique thereof, and application in the field of medicine, animal husbandry, food or chemical industry. The yeast strain includes first and second gene modifications, wherein the first gene includes protein kinase A (PKA) catalytic subunit encoding genes TPK1, TPK2 and TPK3, by modifying the first gene, the activity or expression of PKA is completely inhibited, so that feedback inhibition to cyclic adenosine monophosphate (cAMP) is eliminated, but at the same time, the growth of the yeast is inhibited; and the second gene modification eliminates growth inhibition caused by the first gene modification, so that the yeast grows normally, and the cAMP yield by the yeast is increased, wherein the increase of the cAMP yield is relative to the cAMP yield by an unmodified yeast. The yeast strain further includes third and / or fourth gene modifications. The recombinant yeast strain of the present invention can stably, continuously and efficiently produce extracellular cAMP by up to 9721.6 μmol / L.

Disclosed is a composition for diagnosing cancer, including an agent for measuring PKA (Protein Kinase A) activity.

The present invention relates to a method of detecting the presence of cancer by measuring the level of enzyme activity and autoantibodies in the blood of an individual. In particular the present invention relates to methods for measurement of activated cAMP-dependent protein kinase A (PKA) activity and antibodies to PKA, a kit for activated PKA activity measurement, and the use of the measured levels of these analytes for determining the presence of cancer.

The invention provides a yeast strain capable of excessively synthesizing extracellular cAMP, a constructing method and a fermentation technology thereof, and an application of the yeast strain in the fields of medicines, livestock husbandry, foods, health foods or chemical industry. The yeast strain comprises first gene modification and second gene modification, wherein the first genes are protein kinase A (PKA) catalytic subunit coding genes TPK1, TPK2 and TPK3, the first genes are modified to completely inhibit the activity or expression of the PKA in order to eliminate the feedback inhibition of cyclic adenosine monophosphate (cAMP) and inhibit the growth of yeast, and the second gene modification eliminates the first gene modification induced growth inhibition in order to make yeast grow normally and increase the cAMP yield of the yeast. The yeast strain further includes third gene modification, fourth gene modification, and / or fifth gene modification. The recombinant yeast strain can stably, continuously and highly-efficiently produce the extracellular cAMP.